Abstract
Complement-mediated cytotoxicity for porcine islet cells (PICs) was evaluated using sera of six animal species. Soluble complement receptor type-1 (sCR1) was added to these sera to examine changes in the 50% hemolytic unit of complement serum (CH50) and the cytotoxic effect on PICs. While all sera except for pig showed cytotoxicity, the extent varied significantly between species. In rat and human serum, sCR1 significantly reduced CH50 and cytotoxicity; however, it had no suppressive effects in dog serum. These results suggest that complement is a primary factor in humoral cytotoxicity for PICs and that complement compatibility with PICs is highly species-specific.
Introduction
Type-1 diabetes mellitus treatment through pancreatic islet cell transplantation is limited by a shortage of human donors, making porcine (pig) islet cells a viable alternative. However, xenotransplantation faces the significant hurdle of Hyperacute Rejection (HAR), primarily driven by the complement system—a complex cascade of proteins in the blood that identifies and destroys foreign cells. This study investigates how the complement systems of different species react to porcine islet cells (PICs) to better understand species-specific rejection and the efficacy of anti-complement agents like sCR1.
Methods
PICs were isolated from adult pig pancreases and exposed to sera from six species: rabbit, guinea pig, rat, dog, pig, and human. Cell viability was measured using the WST-8 assay, and total complement activity was assessed via CH50 titration. To test potential therapeutic intervention, soluble complement receptor type-1 (sCR1), a recombinant protein designed to block the complement cascade, was introduced to the sera.
Results
Species-Specific Cytotoxicity
The study found that dog and rabbit sera were the most toxic to PICs. At a 12.5% serum concentration, PIC survival in dog serum was only 36.9%. In contrast, human serum was the most "gentle" among the foreign species, with a survival rate of 90.7% even at a 50% concentration.
Efficacy of sCR1 Inhibition
The inhibitory effect of sCR1 was highly dependent on the species of the serum. In human and rat sera, sCR1 effectively suppressed complement activity and restored PIC survival. For instance, sCR1 suppressed human complement activity down to 1.2% of its original strength. However, sCR1 failed to provide any protection in dog serum, highlighting a significant structural or functional mismatch between the human-derived inhibitor and the canine complement system.
Discussion
The failure of sCR1 in dog serum suggests a structural mismatch where the inhibitor fails to interact with dog complement proteins. The relative compatibility of human serum is an encouraging sign for pig-to-human xenotransplantation. Additionally, the presence of rejection in adult pig islets—which often lack the Gal antigen—indicates that other, less-understood antigens are likely triggering the complement system.
Conclusion
Complement-mediated cytotoxicity is a major factor in the rejection of porcine islet cells, but its impact is highly species-specific. While human serum shows promising compatibility, the failure of inhibitors in certain animal models like dogs underscores the complexity of cross-species immunological interactions and the need for targeted, species-appropriate therapeutic strategies.
Summary updated